Table 1 Socio-demographic, clinical and therapeutic characteristics of BiobadaBrasil patients included in the present study (n = 105). Values are numbers (%), unless stated otherwise
Negative serology n = 55 | Positive serology (IgG) n = 50 | All patients (n = 105) | ||
|---|---|---|---|---|
Asymptomatic (n = 18) | Symptomatic (n = 32) | |||
Female | 41 (74.5) | 12 (66.7) | 25 (78.1) | 78 (74.3) |
Age – years; mean (SD) | 50.3 (13.3) | 46.3 (15.2) | 52.2 (12.7) | 50.2 (13.7) |
Non-Caucasian | 40 (72.7) | 13 (72.2) | 24 (75.0) | 77 (73.3) |
Rheumatic disease RA AS PsA | 43 (78.2) 8 (14.5) 4 (7.3) | 13 (72.2) 5 (27.8) 0 (0.0) | 28 (87.5) 4 (12.5) 0 (0.0) | 84 (80.0) 17 (16.2) 4 (3.8) |
Disease duration – years; median (IQR) | 9.0 (4.0–15.0) | 7.0 (3.8–11.8) | 13.0 (5.2 to 17.8) | 9.0 (4.5–15.0) |
csDMARD use Methotrexate Leflunomide Antimalarials Sulfasalazine | 21 (38.2) 14 (25.5) 3 (5.5) 4 (7.3) | 12 (66.7) 4 (22.2) 0 (0.0) 1 (5.6) | 17 (53.1) 9 (28.1) 4 (12.5) 1 (3.1) | 50 (47.6) 27 (25.7) 7 (6.7) 6 (5.7) |
bDMARD use Anti-TNF Abatacept Rituximab Tocilizumab | 25 (45.5) 3 (5.5) 5 (9.1) 2 (3.6) | 8 (44.4) 0 (0.0) 1 (5.6) 0 (0.0) | 11 (34.4) 1 (3.1) 1 (3.1) 1 (3.1) | 44 (41.9) 4 (3.8) 7 (6.7) 3 (2.9) |
IgM for CHIKV Positive Borderline Negative Not tested | 0 (0.0) 1 (1.8) 54 (98.2) 0 (0.0) | 8 (44.4) 1 (5.6) 9 (50.0) 0 (0.0) | 9 (28.1) 8 (25.0) 13 (40.6) 2 (6.2) | 17 (16.2) 10 (9.5) 76 (72.4) 2 (2.0) |